234 related articles for article (PubMed ID: 23389975)
1. [Protective effects of snake venom antimicrobial peptide OH-CATH on E. coli induced rabbit urinary tract infection models].
Zhang BY; Li SM; Gao ZH; Shen JH
Dongwuxue Yanjiu; 2013 Feb; 34(1):27-32. PubMed ID: 23389975
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in southern Switzerland.
Borsari AG; Bucher B; Brazzola P; Simonetti GD; Dolina M; Bianchetti MG
Clin Ther; 2008 Nov; 30(11):2090-5. PubMed ID: 19108796
[TBL] [Abstract][Full Text] [Related]
3. CATH-2-derived antimicrobial peptide inhibits multidrug-resistant
Hao S; Shi W; Chen L; Kong T; Wang B; Chen S; Guo X
Front Cell Infect Microbiol; 2024; 14():1390934. PubMed ID: 38812753
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of catheter-associated urinary tract infections and multi-drug-resistant Escherichia coli isolates from the urine of dogs with indwelling urinary catheters.
Ogeer-Gyles J; Mathews K; Weese JS; Prescott JF; Boerlin P
J Am Vet Med Assoc; 2006 Nov; 229(10):1584-90. PubMed ID: 17107313
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates.
Lin CY; Huang SH; Chen TC; Lu PL; Lin WR; Chen YH
J Microbiol Immunol Infect; 2008 Aug; 41(4):325-31. PubMed ID: 18787740
[TBL] [Abstract][Full Text] [Related]
6. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
[TBL] [Abstract][Full Text] [Related]
7. Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups.
Ali I; Shabbir M;
J Pak Med Assoc; 2017 Aug; 67(8):1161-1165. PubMed ID: 28839298
[TBL] [Abstract][Full Text] [Related]
8. Intravesical hyaluronic acid and chondroitin sulfate alone and in combination for urinary tract infection: assessment of protective effects in a rat model.
Tasdemir S; Tasdemir C; Vardi N; Yakupogullari Y; Duman Y; Parlakpinar H; Sagir M; Acet A
Int J Urol; 2012 Dec; 19(12):1108-12. PubMed ID: 22852837
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of an antibacterial peptide analog against uropathogens.
Cudic M; Lockatell CV; Johnson DE; Otvos L
Peptides; 2003 Jun; 24(6):807-20. PubMed ID: 12948832
[TBL] [Abstract][Full Text] [Related]
10. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.
Greenberg RN; Reilly PM; Weinandt WJ; Bollinger M; Kennedy DJ
Clin Ther; 1987; 10(1):52-6. PubMed ID: 3329965
[TBL] [Abstract][Full Text] [Related]
11. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
Jakobsen L; Cattoir V; Jensen KS; Hammerum AM; Nordmann P; Frimodt-Møller N
J Antimicrob Chemother; 2012 Oct; 67(10):2438-44. PubMed ID: 22685162
[TBL] [Abstract][Full Text] [Related]
12. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
13. Intravesical nitric oxide delivery for prevention of catheter-associated urinary tract infections.
Carlsson S; Weitzberg E; Wiklund P; Lundberg JO
Antimicrob Agents Chemother; 2005 Jun; 49(6):2352-5. PubMed ID: 15917532
[TBL] [Abstract][Full Text] [Related]
14. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients.
Sanchez GV; Baird AM; Karlowsky JA; Master RN; Bordon JM
J Antimicrob Chemother; 2014 Dec; 69(12):3259-62. PubMed ID: 25063776
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of anti-microbial resistance of Escherichia coli that caused infection in urogenital system].
Cui WL; Xu DX; Li WL; Wang LX
Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):940-2, 945. PubMed ID: 15321769
[TBL] [Abstract][Full Text] [Related]
16. Trends in antimicrobial susceptibility of Escherichia coli isolates from urology services in The Netherlands (1998-2005).
Nys S; Terporten PH; Hoogkamp-Korstanje JA; Stobberingh EE;
J Antimicrob Chemother; 2008 Jul; 62(1):126-32. PubMed ID: 18417487
[TBL] [Abstract][Full Text] [Related]
17. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition.
Smith SP; Manges AR; Riley LW
Clin Infect Dis; 2008 Mar; 46(5):689-95. PubMed ID: 18230040
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefoperazone-sulbactam: Singapore experience.
Kumarasinghe G; Chow C; Chiu C; Cheong YM
Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):734-7. PubMed ID: 9253876
[TBL] [Abstract][Full Text] [Related]
19. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice.
Håversen LA; Engberg I; Baltzer L; Dolphin G; Hanson LA; Mattsby-Baltzer I
Infect Immun; 2000 Oct; 68(10):5816-23. PubMed ID: 10992490
[TBL] [Abstract][Full Text] [Related]
20. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli.
Ejrnæs K
Dan Med Bull; 2011 Apr; 58(4):B4187. PubMed ID: 21466767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
